Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial (Q33905053)

29 July 2017

title

Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial (English)

1 reference

29 July 2017

main subject

phase I clinical trial

0 references

author name string

Markert JM

1

1 reference

29 July 2017

Medlock MD

2

1 reference

29 July 2017

Rabkin SD

3

1 reference

29 July 2017

Gillespie GY

4

1 reference

29 July 2017

Todo T

5

1 reference

29 July 2017

Hunter WD

6

1 reference

29 July 2017

Palmer CA

7

1 reference

29 July 2017

Feigenbaum F

8

1 reference

29 July 2017

Tornatore C

9

1 reference

29 July 2017

Tufaro F

10

1 reference

29 July 2017

Martuza RL

11

1 reference

29 July 2017

publication date

1 May 2000

1 reference

29 July 2017

1 reference

29 July 2017

volume

7

1 reference

29 July 2017

issue

10

1 reference

29 July 2017

page(s)

867-874

1 reference

Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery

29 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301205

7 January 2021

Highly anaplastic astrocytoma: a review of 357 patients treated between 1977 and 1989

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301205

7 January 2021

Salvage chemotherapy with taxol for recurrent anaplastic astrocytomas

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301205

7 January 2021

Experimental Therapy of Human Glioma by Means of a Genetically Engineered Virus Mutant

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301205

7 January 2021

Attenuated multi–mutated herpes simplex virus–1 for the treatment of malignant gliomas

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301205

7 January 2021

Attenuated, replication-competent herpes simplex virus type 1 mutant G207: safety evaluation in mice

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301205

7 January 2021

Systemic antitumor immunity in experimental brain tumor therapy using a multimutated, replication-competent herpes simplex virus

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301205

7 January 2021

Cerebral tumor volume calculations using planimetric and eigenimage analysis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301205

7 January 2021

Therapeutic replication-competent herpes virus

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301205

7 January 2021

Development of multiple lesions during radiation therapy and chemotherapy in patients with gliomas

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301205

7 January 2021

Extraneural metastases of astrocytomas and glioblastomas: clinicopathological study of two cases and review of literature

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301205

7 January 2021

Changes in prevalence of herpes simplex virus type 1 and 2 antibodies from 1973 to 1993 in the rural districts of Japan

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301205

7 January 2021

Reduction and elimination of encephalitis in an experimental glioma therapy model with attenuated herpes simplex mutants that retain susceptibility to acyclovir

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301205

7 January 2021

Herpes simplex virus as an in situ cancer vaccine for the induction of specific anti-tumor immunity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301205

7 January 2021

Treatment of intracranial gliomas in immunocompetent mice using herpes simplex viruses that express murine interleukins

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301205

7 January 2021

Identifiers

DOI

10.1038/SJ.GT.3301205

1 reference

29 July 2017

1 reference